ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "antiphospholipid syndrome"

  • Abstract Number: 1071 • 2016 ACR/ARHP Annual Meeting

    Anti-β2GP-I-Domain 3 and Aps/PT-IgG Antibodies Identify Primary APS Patients with Both Thrombotic and Hematological Manifestations

    Diego Hernández-Ramírez1, Gabriela Hernandez-Molina2, Carlos Núñez-Álvarez3, Miguel Astudillo-Angel4, Carlos Pacheco1, Elizabeth Olivares-Martínez1 and Antonio R. Cabral5, 1Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 2Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico City, Mexico, 3Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion S.Z., Mexico city, Mexico, 4Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 5Department of Medicine. Division of Rheumatology, The Ottawa Hospital.University of Ottawa, Ottawa, ON, Canada

    Background/Purpose: Thrombocytopenia and hemolytic anemia (HA) are considered non-criteria clinical manifestations by the Sydney revised criteria for APS. These features can precede, follow a thrombotic…
  • Abstract Number: 1072 • 2016 ACR/ARHP Annual Meeting

    Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: Cardiovascular Risk Factors Among Different Groups of Antiphospholipid Antibody-Positive Patients

    Ozan Unlu1, Doruk Erkan2, Maria Tektonidou3 and On Behalf of APS ACTION .4, 1Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 2Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, 3First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, 4., New York, NY

    Background/Purpose: Traditional cardiovascular disease (CVD) risk factors increase the risk of thrombotic clinical manifestations in antiphospholipid antibody (aPL)-positive patients.  The prevalence of CVD risk factors…
  • Abstract Number: 1962 • 2016 ACR/ARHP Annual Meeting

    Antiphospholipid Syndrome Neutrophils Are Characterized By Overexpression of P-Selectin Glycoprotein Ligand 1, a Potential Therapeutic Target

    Jason S Knight1, Patrick S. Coit1, He Meng1, Srilakshmi Yalavarthi1, Paul Renauer1, Robert C Grenn1, Levi F Mazza1, Hui Wang2, Daniel T Eitzman2 and Amr H Sawalha1, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI

    Background/Purpose:  Treatment of the thrombotic manifestations of antiphospholipid syndrome (APS) primarily focuses on inhibiting clotting pathways. In an effort to identify upstream inflammatory targets that…
  • Abstract Number: 1965 • 2016 ACR/ARHP Annual Meeting

    Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: First and Recurrent Thrombosis Risk after 720 Patient-Years of Follow-up

    Ozan Unlu1, W. David Branch2, Paul R. Fortin3, Maria Gerosa4, Guillermo J. Pons-Estel5, Maria Tektonidou6, Amaia Ugarte7, Doruk Erkan8 and On Behalf of APS ACTION .9, 1Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 2Obstetrics and Gynecology, University of Utah and Intermountain Healthcare, Salt Lake City, UT, 3Medicine, CHU de Québec - Université Laval, Québec, QC, Canada, 4University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, 5Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, 6First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, 7Hospital Universitario Cruces, Biscay, Spain, 8Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, 9., New York, NY

    Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients. Previously, based on…
  • Abstract Number: 2086 • 2016 ACR/ARHP Annual Meeting

    Hexagonal Phase Phospholipid Neutralization Assay Is the Most Sensitive but Least Specific Among Nine Tests for Detecting APS in SLE or Non-SLE Patients

    Katalin Banki1, Phillip Aleksiejuk2, Jessica Patel2 and Andras Perl3, 1Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY, 2Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, 3Department of Medicine, Upstate Medical University, Syracuse, NY

    Background/Purpose: Antiphospholipid antibody syndrome (APS) is an autoimmune, hypercoagulable state which may elicit thrombosis and pregnancy loss.  Although several tests exist to guide diagnosis of…
  • Abstract Number: 2087 • 2016 ACR/ARHP Annual Meeting

    A Type I Interferon Signature in Monocytes and Decreased Levels of Circulating Plasmacytoid Dendritic Cells in Patients with Primary Antiphospholipid Syndrome

    Lucas L. van den Hoogen1, Ruth D.E. Fritsch-Stork2, Marjan A. Versnel3, Ronald H.W.M. Derksen4, Joel A.G. van Roon5,6 and Timothy R.D.J. Radstake5,6, 1Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3Immunology, Erasmus Medical Center, Rotterdam, Netherlands, 4Departments of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 5Laboratory of Translational Immunology, UMC Utrecht, Utrecht, Netherlands, 6Department of Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands

    Background/Purpose: In several autoimmune diseases, most notably in systemic lupus erythematosus (SLE), a type I interferon (IFN) signature has been described. This signature is thought…
  • Abstract Number: 2090 • 2016 ACR/ARHP Annual Meeting

    Investigating the Genetic Variations of Antiphospholipid Syndrome By High-Throughput Exome Sequencing

    Sung-Hoon Park1, Chan Uk Lee1, Ji Na Kim2, Ji-Won Kim1, Hwajeong Lee2, Seong-Kyu Kim2 and Jung-Yoon Choe1, 1Medicine, Catholic university of Daegu School of medicine, Daegu, Korea, The Republic of, 2Catholic university of Daegu School of medicine, Daegu, Korea, The Republic of

    Background/Purpose:  The antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of antiphospholipid antibodies in serum together with clinical manifestations such as thrombosis,…
  • Abstract Number: 2092 • 2016 ACR/ARHP Annual Meeting

    Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 Is Elevated in Patients with Thrombotic Primary Antiphospholipid Syndrome.  

    Yair Molad1,2, Yonatan Edel3,4, Yael Pri-Paz Basson5, Elisheva Pokroy-Shapira6, Shirly Oren5, Ariela Dortort5 and Vitaly Kliminski4,7, 1Rheumatology Unit, Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, 2Laboratory of Inflammation Research, Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, 3Department of Medicine C, Beilinson Hospital, Rabib Medical Center, Petach Tikva, Israel, 4Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 5Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel, 6Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, 7Laboratory of Inflammation Research, Felsenstein Medical Research Center, Rabin Medical Center, Petach Tikva, Israel

    Background/Purpose : Primary antiphospholipid syndrome (PAPS) is characterized by thrombotic and/or obstetrical morbidity in the presence of persistent antiphospholipid antibodies (APLA) and in the absence…
  • Abstract Number: 1854 • 2015 ACR/ARHP Annual Meeting

    Identification and Characterization of microRNAs Related to the Pathogenesis of Cardiovascular Disease in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus. Role of Specific Autoantibodies

    Chary Lopez-Pedrera1, Maria Ángeles Aguirre Zamorano1, Patricia Ruiz-Limon1, Nuria Barbarroja1, Yolanda Jiménez Gómez1, Eduardo Collantes-Estevez1, Mª Jose Cuadrado2, Rocio Gonzalez-Conejero3, Constantino Martinez3 and Carlos Perez-Sanchez1, 1IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, 2Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, 3Regional Centre for Blood Donation, University of Murcia, Murcia, Spain

    Background/Purpose: 1) To identify and characterize miRNAs related to the pathogenesis of CVD in antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) patients; 2) To…
  • Abstract Number: 2945 • 2015 ACR/ARHP Annual Meeting

    Diffuse Alveolar Hemorrhage in SLE:  Risk Factors, Response to Therapy, and Survival

    Nayef M. Kazzaz1, Patrick S. Coit2, Emily E. Lewis3, W Joseph McCune4, Amr H. Sawalha2 and Jason S. Knight2, 1Rheumatology, University of Michigan, Ann Arbor, MI, 2Division of Rheumatology, University of Michigan, Ann Arbor, MI, 3University of Michigan, Ann Arbor, MI, 4Int Med/ Rheum, University of Michigan, Ann Arbor, MI

    Background/Purpose:  While diffuse alveolar hemorrhage (DAH) is recognized as a life-threatening complication of SLE, little is known about its risk factors and response to therapy. …
  • Abstract Number: 2000 • 2015 ACR/ARHP Annual Meeting

    Immune Response Against  β2GPI Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome

    Pier Luigi Meroni1,2, Marisa Benagiano3, Maria Gerosa4, Jacopo Romagnoli5, Michael Mahler6, Maria Orietta Borghi7,8, Alessia Grassi9, Chiara Della Bella3, Giacomo Emmi3, Amedeo Amedei3,10, Elena Silvestri3, Lorenzo Emmi11, Domenico Prisco9,10 and Mario Milco D'Elios3,10, 1Clinical Sciences and Community Heath, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, 2Laboratory of Immuno-rheumatology, Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Cusano Milanino, Italy, 3Department of Experimental and Clinical Medicine, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 4Division of Rheumatology, Department of Clinical Sciences and Community Health, Ospedale Gaetano Pini, University of Milan, Milano, Italy, 5Department of Surgery, Department of Surgery, Catholic University of Rome, Rome, Italy, 6Inova Diagnostics, San Diego, CA, 7Department of Clinical Sciences and Community Health, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, 8Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Milan, Italy, 9Department of Experimental and Clinical Medicine,, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 10Internal Interdisciplinary Medicine Center for Autoimmune Systemic Diseases, Lupus Clinic, Internal Interdisciplinary Medicine Center for Autoimmune Systemic Diseases, Lupus Clinic, AOU Careggi, Florence, Italy, 11Internal Interdisciplinary Medicine Center for Autoimmune Systemic Diseases, Lupus Clinic,, Internal Interdisciplinary Medicine Center for Autoimmune Systemic Diseases, Lupus Clinic, AOU Careggi, Florence, Italy

    Background/Purpose: Antiphospholipid syndrome (APS) is characterized by the presence of arterial and venous thrombosis, and by recurrent abortions, in patients with persistent presence of autoantibodies…
  • Abstract Number: 3124 • 2015 ACR/ARHP Annual Meeting

    Associations of Circulating Cell-Free Micro-RNA with Vasculopathy and Vascular Events in SLE Patients

    Susan Due Kay1, Anting L. Carlsen2, Anne Voss1, Mikael Kjær Poulsen3, Axel Cosmus Pyndt Diederichsen4 and Niels H. H. Heegaard5, 1Department of Rheumatology, Odense University Hospital, Odense C, Denmark, 2Department of Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark, 3Department of Cardiology, Odense University Hospital, Odense C, Denmark, 4Department of Cardiology,, Odense University Hospital, Odense C, Denmark, 5Department of Clinical Biochemistry & Pharmacology, Odense University Hospital, Odense C, Denmark

    Background/Purpose: MicroRNAs (miRNAs) are small noncoding RNAs that modulate protein translation and regulate numerous immunologic and inflammatory pathways. Certain miRNA profiles have been associated with…
  • Abstract Number: 2003 • 2015 ACR/ARHP Annual Meeting

    Primary Antiphospholipid Syndrome Is Characterized By Endothelial Progenitor Dysfunction and a Type I Interferon Signature

    Robert C. Grenn1, Srilakshmi Yalavarthi2, Paula L. Bockenstedt3 and Jason S. Knight2, 1University of Michigan, Ann Arbor, MI, 2Division of Rheumatology, University of Michigan, Ann Arbor, MI, 3Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI

    Background/Purpose:  Patients with primary antiphospholipid syndrome (APS) are at risk for endothelial dysfunction and accelerated atherosclerosis.  In systemic lupus erythematosus (SLE), there is a well-established…
  • Abstract Number: 2005 • 2015 ACR/ARHP Annual Meeting

    Circulating Mirnas As Potential Disease Biomarkers in Antiphospholipid Syndrome Patients

    Carlos Perez-Sanchez1, Mihaela Diana Ivanoiu1, Maria Ángeles Aguirre Zamorano1, Patricia Ruiz-Limon1, Nuria Barbarroja1, Yolanda Jiménez Gómez1, Maria Carmen Abalos-Aguilera1, Rocio Gonzalez-Conejero2, Constantino Martinez2, Eduardo Collantes-Estevez1, Mª Jose Cuadrado3 and Chary Lopez-Pedrera1, 1IMIBIC-Reina Sofia University Hospital, Rheumatology Unit, Cordoba, Spain, 2Regional Centre for Blood Donation, University of Murcia, Murcia, Spain, 3Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, United Kingdom

    Background/Purpose: Epigenetic anomalies are emerging as striking pathogenic features of autoimmune disorders. MicroRNAs (miRNAs) are small non-coding RNAs with a key role in regulatory networks that…
  • Abstract Number: 2174 • 2015 ACR/ARHP Annual Meeting

    Neutrophils in Primary Antiphospholipid Syndrome Are Characterized By a Prominent Activated Phenotype and Uniquely Remodeled Chromatin Architecture

    Patrick Coit, Srilakshmi Yalavarthi, Jason S. Knight and Amr H. Sawalha, Division of Rheumatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by recurrent thrombotic events, pregnancy complications, and the presence of antiphospholipid antibodies. The pathogenesis of…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology